tiprankstipranks
VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202
PremiumThe FlyVYNE Therapeutics announces results from Phase 1a SAD trial for VYN202
3M ago
VYNE Therapeutics sees cash runway through end of 2025
Premium
The Fly
VYNE Therapeutics sees cash runway through end of 2025
4M ago
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year
Premium
The Fly
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year
4M ago
VYNE Therapeutics announces dosing of first subject in Phase 2b trial of VYN201
PremiumThe FlyVYNE Therapeutics announces dosing of first subject in Phase 2b trial of VYN201
7M ago
VYNE Therapeutics expects cash to fund operations through 2025
Premium
The Fly
VYNE Therapeutics expects cash to fund operations through 2025
8M ago
VYNE Therapeutics reports Q1 EPS (15c) vs. ($1.74) last year
Premium
The Fly
VYNE Therapeutics reports Q1 EPS (15c) vs. ($1.74) last year
8M ago
VYNE Therapeutics reports Q4 EPS (20c) vs. ($2.60) last year
PremiumThe FlyVYNE Therapeutics reports Q4 EPS (20c) vs. ($2.60) last year
10M ago
VYNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
VYNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
10M ago
VYNE Therapeutics announces biomarker data from Phase 1b trial of VYN201
Premium
The Fly
VYNE Therapeutics announces biomarker data from Phase 1b trial of VYN201
12M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100